TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10390255

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.25 mg/kg bid for 3 days, then 0.15 mg/kg bid for 3 days, followed by a tapering schedule to 0.1 mg/kg until 42 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 118
Study: 9014716

Group type: EXPERIMENTAL
Intervention: Transurethral electroresection of the prostate (TURP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Transurethral electrovaporization (TUEP) using 240-300 W of cutting current
Number of subjects: 46
Study: 2004805

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6833676

Group type: EXPERIMENTAL
Intervention: Atropine pretreatment followed by high doses of methacholine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cromolyn sodium (40 mg) pretreatment
Number of subjects: 6
Study: 31589864

Group type: EXPERIMENTAL
Intervention: Robotic laparoendoscopic single-site sacrocolpopexy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Multi-port robotic sacrocolpopexy
Number of subjects: 70
Study: 29458915

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 63
Study: 26733462

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard health care (control group)
Number of subjects: 103
Study: 24966097

Group type: COMPARATOR
Intervention: Normal physiological saline (PS)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Oral administration of PS + N-acetylcysteine (NAC)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Oral administration of SB + NAC
Number of subjects: 627
Study: 22306907

Group type: EXPERIMENTAL
Intervention: GC+CIK (gemcitabine and cisplatin plus autologous cytokine-induced killer cell transfusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GC (gemcitabine and cisplatin chemotherapy alone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 60
Study: 20410684

Group type: EXPERIMENTAL
Intervention: PBTM-DM group (pantoprazole 40 mg b.i.d., bismuth citrate 400 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg b.i.d. for 14 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: PCA-DM group (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 14 days)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PBTM-non-DM group (quadruple therapy for 14 days)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Successful eradication in DM patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Unsuccessful eradication in DM patients
Number of subjects: 89
Study: 18545194

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX) with unloaded leg on an inertial resistance ergometer and albuterol (16 mg.d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance exercise (REX) with unloaded leg on an inertial resistance ergometer and placebo (lactose)
Number of subjects: 0
Study: 15503297

Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (10 microg/kg/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (5 microg/kg/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (5 microg/kg/day) and IL‐6 (2.5‐5 microg/kg/day)
Number of subjects: 97
Study: 12425706

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral training (n = 73)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Behavioral training without biofeedback (verbal feedback based on vaginal palpation; n = 74)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Self-administered behavioral treatment using a self-help booklet (control condition; n = 75)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 222
Study: 10512900

Group type: EXPERIMENTAL
Intervention: High lipoprotein(a) levels in female cases
Number of subjects: 302

Group type: COMPARATOR
Intervention: Plasma Lp(a) levels
Number of subjects: 302

Group type: COMPARATOR
Intervention: C pneumoniae-specific IgG or IgA antibodies
Number of subjects: 302

Group type: COMPARATOR
Intervention: Antibody titers
Number of subjects: 302

Group type: COMPARATOR
Intervention: C pneumoniae IgG titer in combination with high Lp(a) level
Number of subjects: 302
Study: 7540922

Group type: EXPERIMENTAL
Intervention: PDD subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: N subjects
Number of subjects: 20
Study: 1781524

Group type: EXPERIMENTAL
Intervention: bupivacaine plus fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 30
Study: 6171898

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 12 mg per kg daily of 5‐FU for four consecutive days, then 6 mg per kg on alternate days to the point of toxicity or to a maximum of five doses, followed by 12 mg per kg weekly for one year
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 5‐FU chemotherapy
Number of subjects: 319
Study: 30629465

Group type: EXPERIMENTAL
Intervention: Resin infiltrant (Icon)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sealant (Helioseal Clear)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adhesive (Adper Scotchbond Multi‐Purpose Plus)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study: 30573125

Group type: EXPERIMENTAL
Intervention: Uninterrupted rivaroxaban
Number of subjects: 127
Study: 27388566

Group type: EXPERIMENTAL
Intervention: Stent Graft (SG)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 270
Study: 24857044

Group type: EXPERIMENTAL
Intervention: Capecitabine/Erlotinib followed by Gemcitabine (CEG)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Erlotinib followed by Capecitabine (GEC)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Gemcitabine (at any time during study treatment)
Number of subjects: 274
Study: 22308054

Group type: EXPERIMENTAL
Intervention: Licorice root extract (2g aqueous extract per day for 2 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 21336431

Group type: EXPERIMENTAL
Intervention: Meat enriched in walnut paste (WM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fat meat (LM)
Number of subjects: 22
Study: 18724189

Group type: EXPERIMENTAL
Intervention: Eban HIV intervention condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Health Promotion condition
Number of subjects: 0
Study: 15936560

Group type: EXPERIMENTAL
Intervention: Breast-conservation therapy (BCT)
Number of subjects: 121
Study: 12658913

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/day) or Olanzapine (10 mg/day)
Number of subjects: 17
Study: 11111259

Group type: EXPERIMENTAL
Intervention: Experimental program (Choices)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 168
Study: 8874658

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 500 micrograms bid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched placebo (P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between BDP and placebo
Number of subjects: 20
Study: 8253362

Group type: EXPERIMENTAL
Intervention: Time-dependent Cox regression model
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Time-dependent Cox regression model with histological variables
Number of subjects: 237
Study: 3020725

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) skin scarification
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control subjects (not receiving BCG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Patients not in the study
Number of subjects: 96

Group type: COMPARATOR
Intervention: T1N0 patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: T2N0 patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: All patients
Number of subjects: 96
Study: 31499397

Group type: EXPERIMENTAL
Intervention: Active manual exploration training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Observational manual exploration training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 50
Study: 30231252

Group type: EXPERIMENTAL
Intervention: BNO 1045
Number of subjects: 659

Group type: COMPARATOR
Intervention: Fosfomycin Trometamol (FT)
Number of subjects: 659
Study: 26612385

Group type: EXPERIMENTAL
Intervention: Restricted sleep (4.5 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal sleep (8.5 h)
Number of subjects: 0
Study: 24050121

Group type: COMPARATOR
Intervention: Semi-vegetarians (n=37)
Number of subjects: 272
Study: 22189827

Group type: EXPERIMENTAL
Intervention: cyclosporine A 0.05% eye drops (one drop twice daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: preservative‐free hyaluronic acid artificial tears (one drop 5 times per day)
Number of subjects: 62
Study: 21055092

Group type: EXPERIMENTAL
Intervention: Enterovirus universal type in HFMD patients
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: EV71 in HFMD patients
Number of subjects: 154

Group type: COMPARATOR
Intervention: Enterovirus universal type in suspected herpangina
Number of subjects: 154

Group type: COMPARATOR
Intervention: EV71 in suspected herpangina
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: EV71 positive rate in severe HFMD
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: EV71 positive rate in mild HFMD
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Age comparison between mild and severe HFMD
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Gender comparison between mild and severe HFMD
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Virus load comparison between mild and severe HFMD
Number of subjects: 154
Study: 17582281

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/d
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/d (after titration)
Number of subjects: 304

Group type: COMPARATOR
Intervention: atorvastatin 10 mg/d
Number of subjects: 304
Study: 15616082

Group type: EXPERIMENTAL
Intervention: 3 microg/kg clonidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 48
Study: 12067198

Group type: EXPERIMENTAL
Intervention: Random item placement format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grouped item placement format
Number of subjects: 0
Study: 10195533

Group type: COMPARATOR
Intervention: 0 mg meperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg meperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg meperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg meperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg meperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg meperidine
Number of subjects: 0
Study: 7594664

Group type: EXPERIMENTAL
Intervention: PncOMPC vaccine (tetravalent pneumococcal conjugate vaccine)
Number of subjects: 93
Study: 2263084

Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 micrograms)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6104131

Group type: EXPERIMENTAL
Intervention: Soluble aspirin given by mouth in therapeutic doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive therapy without specific drug treatment
Number of subjects: 0
Study: 31025924

Group type: EXPERIMENTAL
Intervention: 40 mg of subcutaneous NTK
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 80 mg of subcutaneous NTK
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 120 mg of subcutaneous NTK
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 31454263

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1641
Study: 27989775

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 25224929

Group type: EXPERIMENTAL
Intervention: IM twice/day (α1-blocker + 0.1 mg imidafenacin twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IM nightly (α1-blocker + 0.1 mg imidafenacin nightly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (α1-blocker alone)
Number of subjects: 0
Study: 24574836

Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold (QFT-Gold) test
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Negative TST results in RA patients
Number of subjects: 143
Study: 22837306

Group type: EXPERIMENTAL
Intervention: CTRP-3
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PEDF
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: CTRP-3 and PEDF
Number of subjects: 345
Study: 19926098

Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Caffeine treatment started early
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Caffeine treatment started late
Number of subjects: 2006
Study: 17707720

Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg administered orally before ovulation (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg administered orally after ovulation (Group B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg administered (both groups)
Number of subjects: 15
Study: 16075231

Group type: EXPERIMENTAL
Intervention: Autologous patellar bone‐tendon‐bone (BTB) grafts
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hamstring tendon (ST) grafts
Number of subjects: 79
Study: 12625150

Group type: EXPERIMENTAL
Intervention: tafenoquine (3‐d)
Number of subjects: 586

Group type: COMPARATOR
Intervention: primaquine (14‐d)
Number of subjects: 586
Study: 9865208

Group type: EXPERIMENTAL
Intervention: Low energy photon therapy (LEPT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9
Study: 8560536

Group type: EXPERIMENTAL
Intervention: Oral inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine, 2 doses, 2 weeks apart
Number of subjects: 346

Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo, 2 doses, 2 weeks apart
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Oral inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine
Number of subjects: 346

Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo
Number of subjects: 346
Study: 2482650

Group type: EXPERIMENTAL
Intervention: RU 486, 25 mg twice daily for 4 days (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RU 486, 25 mg for 3 days (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of sulprostone, 0.25 mg on the last day of RU 486 treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plasma beta‐hCG and progesterone levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels
Number of subjects: 40
Study: 7209671

Group type: EXPERIMENTAL
Intervention: Fusion with instrumentation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laminectomy with fusion and instrumentation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laminectomy alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laminectomy with fusion without instrumentation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fusion alone
Number of subjects: 63

Group type: COMPARATOR
Intervention: No operation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Detailed rehabilitation program
Number of subjects: 63
Study: 31367979

Group type: EXPERIMENTAL
Intervention: EX‐PRESS glaucoma filtration device implantation
Number of subjects: 32
Study: 28733855

Group type: COMPARATOR
Intervention: Professional Development provided by trained Ugandan mental health professionals to Ugandan primary school teachers; included large‐group experiential training and small‐group coaching; duration of 4-5 months.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Wait-list control condition; no specific intervention details provided.
Number of subjects: 79
Study: 26446696

Group type: EXPERIMENTAL
Intervention: Single training of GPs in the pharmacological management of HF drug therapy according to ESC guidelines
Number of subjects: 30

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 30
Study: 23414504

Group type: EXPERIMENTAL
Intervention: Cocaine cholera toxin B conjugate vaccine
Number of subjects: 55
Study: 21550906

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 6789

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 6789
Study: 19735396

Group type: EXPERIMENTAL
Intervention: Trainees
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Experts
Number of subjects: 32
Study: 19635069

Group type: EXPERIMENTAL
Intervention: Triple-site CRT-D
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard CRT-D
Number of subjects: 100
Study: 15281472

Group type: EXPERIMENTAL
Intervention: Butterbur, 50 mg twice daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15460761

Group type: EXPERIMENTAL
Intervention: Web-based randomisation service
Number of subjects: 0
Study: 9121678

Group type: EXPERIMENTAL
Intervention: Group 1 (n = 8) used emotional strategies (positive emotions for left hemisphere activation, negative emotion for right hemisphere activation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Group 2 (n = 8) received no guidance
Number of subjects: 16
Study: 8214745

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (1.5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 16
Study: 2447715

Group type: EXPERIMENTAL
Intervention: Dextran Group
Number of subjects: 275

Group type: COMPARATOR
Intervention: Plasma Group
Number of subjects: 275
Study: 11590533

Group type: EXPERIMENTAL
Intervention: GW420867X 50 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GW420867X 100 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GW420867X 200 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (GW420867X, 3TC, and ZDV placebos)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GW420867X (all doses combined)
Number of subjects: 60
Study: 29948224

Group type: EXPERIMENTAL
Intervention: Fluid collection bags
Number of subjects: 43

Group type: COMPARATOR
Intervention: Negative control samples (intracapsular tissue samples)
Number of subjects: 43
Study: 26761379

Group type: EXPERIMENTAL
Intervention: Paravertebral block (S group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subarachnoid block (C group)
Number of subjects: 50
Study: 24967813

Group type: EXPERIMENTAL
Intervention: Maternal 25‐OHD deficiency (<37.5 nmol/L)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: For every 25 nmol increase in 25‐OHD concentration in late pregnancy
Number of subjects: 960
Study: 22579034

Group type: EXPERIMENTAL
Intervention: E-learning group with access to the ECOFISIO website
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group with access to documents and books
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: E-learning group
Number of subjects: 46
Study: 20627974

Group type: EXPERIMENTAL
Intervention: Intervention group (n=127) attended four interactive group sessions and received monthly support via text messages for 12 months
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (n=123) attended one non‐interactive information session
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Difference in weight change between intervention and control groups
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Secondary analysis for total cholesterol concentration
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Secondary analysis for self management behaviours (diet score)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Secondary analysis for self management behaviours (physical activity score)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Secondary analysis for confidence to control weight
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Regular self weighing in the intervention group
Number of subjects: 250
Study: 18662191

Group type: EXPERIMENTAL
Intervention: Ranolazine (45 mg/h for 3 hours followed by 90 mg/h for 5 hours)
Number of subjects: 5
Study: 15744450

Group type: EXPERIMENTAL
Intervention: High calcium mineral water (HCaMW) - 1 liter daily (596 mg Ca/l)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo - 1 liter of mineral water with low calcium content (10 mg/l)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High calcium mineral water (HCaMW) with vitamin D (400 iu/day)
Number of subjects: 180
Study: 11796428

Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 3 months followed by inhaled budesonide for 15 months (800 microg bid)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo tablets followed by placebo inhaler therapy
Number of subjects: 189
Study: 10732870

Group type: EXPERIMENTAL
Intervention: BCNU 120 mg/m2 d.l, VP 16 60 mg/in2 d.2‐4, procarbazine 85 mg/m2 d. 2‐8 (Arm A)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 6 mg/m2 d.l with VP16 and procarbazine in the same dosage and schedule (Arm B)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Both arms pooled results
Number of subjects: 47

Group type: COMPARATOR
Intervention: Initial performance status
Number of subjects: 47

Group type: COMPARATOR
Intervention: Presence of significant antecedent and/or concomitant disease (SACD)
Number of subjects: 47
Study: 7745507

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 446

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant and Air placebo
Number of subjects: 446